David Thompson
Corporate Officer/Principal en INOZYME PHARMA, INC. .
Cargos activos de David Thompson
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| INOZYME PHARMA, INC. | Corporate Officer/Principal | 01/07/2021 | - |
Historial de carrera de David Thompson
Antiguos cargos conocidos de David Thompson.
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| INOZYME PHARMA, INC. | Director Técnico/Científico/I+D | 01/04/2018 | 13/10/2020 |
Azure Biotech, Inc.
 Azure Biotech, Inc. BiotechnologyHealth Technology Azure Biotech, Inc. is a private biotechnology company that is developing an alternative product to address the many drawbacks of current therapies for vulvovaginal atrophy (VVA). The company is based in New York, NY. The company has the exclusive worldwide rights to all topical formulations of lasofoxifene, a selective estrogen receptor modulator (SERM). Azure plans to rapidly build upon the extensive safety and efficacy data already available from clinical trials previously completed with an oral formulation in more than 15,000 women. The company was founded by David Thompson. | Fundador | - | - |
| Presidente | - | - |
Formación de David Thompson.
| The University of Montana | Graduate Degree |
| University of Connecticut | Doctorate Degree |
Estadísticas
Internacional
| Estados Unidos | 5 |
Operativa
| Graduate Degree | 2 |
| Chief Tech/Sci/R&D Officer | 1 |
| Founder | 1 |
Sectorial
| Health Technology | 3 |
| Consumer Services | 3 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| INOZYME PHARMA, INC. | Health Technology |
| Empresas privadas | 1 |
|---|---|
Azure Biotech, Inc.
Azure Biotech, Inc. BiotechnologyHealth Technology Azure Biotech, Inc. is a private biotechnology company that is developing an alternative product to address the many drawbacks of current therapies for vulvovaginal atrophy (VVA). The company is based in New York, NY. The company has the exclusive worldwide rights to all topical formulations of lasofoxifene, a selective estrogen receptor modulator (SERM). Azure plans to rapidly build upon the extensive safety and efficacy data already available from clinical trials previously completed with an oral formulation in more than 15,000 women. The company was founded by David Thompson. | Health Technology |
- Bolsa de valores
- Insiders
- David Thompson
- Experiencia
